About the product
Vabysmo (faricimab) 120 mg/mL solution for injection for intravitreal use.
VABYSMO is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
- Macular Edema Following Retinal Vein Occlusion (RVO)
Vabysmo is used in adults to treat nAMD and DMO, which both affect the macula, the central part of the retina responsible for fine, central vision.
- Single-use vial for intravitreal use only.
- Vabysmo must be administered by a qualified physician experienced in intravitreal injections.
- Each vial should only be used for the treatment of a single eye.
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Hypersensitivity
After-care
- If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician’s discretion.
- If visual and/or anatomic outcomes indicate that the patient is not benefiting from continued treatment, Vabysmo should be discontinued.
- No dose modifications of Vabysmo are recommended.
Vabysmo (faricimab) 120 mg/mL solution for injection for intravitreal use.
VABYSMO is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
- Macular Edema Following Retinal Vein Occlusion (RVO)
Vabysmo is used in adults to treat nAMD and DMO, which both affect the macula, the central part of the retina responsible for fine, central vision.
- Single-use vial for intravitreal use only.
- Vabysmo must be administered by a qualified physician experienced in intravitreal injections.
- Each vial should only be used for the treatment of a single eye.
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Hypersensitivity
After-care
- If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician’s discretion.
- If visual and/or anatomic outcomes indicate that the patient is not benefiting from continued treatment, Vabysmo should be discontinued.
- No dose modifications of Vabysmo are recommended.
Related products
Tier pricing
Save 2.51%
3 or more
$389.00 each
Save 3.76%
11 or more
$384.00 each
Save 5.01%
21 or more
$379.00 each
Tier pricing
Save 2.25%
3 or more
$87.00 each
Save 3.37%
11 or more
$86.00 each
Save 4.49%
21 or more
$85.00 each
Tier pricing
Save 1.45%
3 or more
$68.00 each
Save 2.9%
11 or more
$67.00 each
Save 4.35%
21 or more
$66.00 each
Tier pricing
Save 3.6%
3 or more
$134.00 each
Save 5.76%
11 or more
$131.00 each
Save 7.19%
21 or more
$129.00 each
Tier pricing
Save 3.37%
3 or more
$86.00 each
Save 5.62%
11 or more
$84.00 each
Save 6.74%
21 or more
$83.00 each
Tier pricing
Save 3.39%
3 or more
$57.00 each
Save 5.08%
11 or more
$56.00 each
Save 6.78%
21 or more
$55.00 each
Tier pricing
Save 2.02%
3 or more
$97.00 each
Save 3.03%
11 or more
$96.00 each
Save 4.04%
21 or more
$95.00 each
Tier pricing
Save 2.25%
3 or more
$87.00 each
Save 3.37%
11 or more
$86.00 each
Save 4.49%
21 or more
$85.00 each
Products
Cart
Log In
Newsletter
Subscribe for exclusive offers and updates on new arrivals
Share feedback at:
Working Hours
MON - SUN 9AM to 6PM EST
The Most Popular Brands
Med Supply Solutions
Support
Secure checkout is guaranteed with full adherence to PCI DSS payment standards.
Products listed here are guaranteed authentic and manufacturer-sourced.
Pay easily with trusted providers
*Google and Apple Pay are currently only available via a direct link provided by your account manager.
Copyright 2025. Med Supply Solutions